In another pilot clinical trial, treatment with naltrexone resulted in marked inhibition of proinflammatory cytokines levels including IL-1β, IL-6 and TNF-α and reduction of fibromyalgia-associated nociplastic pain (Parkitny and Younger 2017). This evidence concerns the gene IL1B and fibromyalgia.